U.S. Markets closed

Amicus Therapeutics, Inc. (FOLD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
23.24+0.48 (+2.11%)
At close: 1:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close22.76
Open22.81
Bid20.51 x 1200
Ask24.00 x 800
Day's Range22.51 - 23.26
52 Week Range6.25 - 23.26
Volume1,630,048
Avg. Volume2,009,340
Market Cap6.056B
Beta (5Y Monthly)1.50
PE Ratio (TTM)N/A
EPS (TTM)-1.15
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.96
  • Amicus Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference
    GlobeNewswire

    Amicus Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference

    CRANBURY, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference being held virtually on Tuesday, December 1, 2020 at 2:15 p.m. E.T. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.CONTACT:Investors: Amicus Therapeutics Andrew Faughnan Director, Investor Relations afaughnan@amicusrx.com (609) 662-3809Media: Amicus Therapeutics Diana Moore Head of Global Corporate Communications dmoore@amicusrx.com (609) 662-5079FOLD–G

  • Sanofi (SNY) Pompe Disease Drug Gets FDA's Priority Tag
    Zacks

    Sanofi (SNY) Pompe Disease Drug Gets FDA's Priority Tag

    The FDA gives priority review tag to Sanofi's (SNY) avalglucosidase alfa for Pompe disease and Fast Track status to rilzabrutinib for immune thrombocytopenia.

  • Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Reported And Analysts Have Been Lifting Their Price Targets
    Simply Wall St.

    Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Reported And Analysts Have Been Lifting Their Price Targets

    Shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD) will be pleased this week, given that the stock price is up...